Floatz logo

gi-102

Resectable Astrocytoma

Mayo ClinicPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Resectable Astrocytoma cohort.

Asset / SponsorPhaseRating
Niraparib
University of Oklahoma
Phase 2CCC
Pembrolizumab
Mayo Clinic
Phase 2CCC
FLUDEOXYGLUCOSE
Jonsson Comprehensive Cancer Center
Phase 1CC
Eras-801
Jonsson Comprehensive Cancer Center
Phase 1CC

Same molecule, other indications

gi-102 is also rated in:

astrocytoma, IDH-mutant, grade 4Dormant
CCC
Indicative ·
53 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
IDH-wildtype glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →